This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. patients required combined sternotomies. Five patients whose thrombi extended to the right atrium were treated with a cardiac bypass. The complication rate was 53% and the peri-operative mortality rate was 12.5%. The median follow-up interval was 64 months.
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INTRODUCTION
Renal cancer is relatively rare and represents only 3.1% of all adult cancers. 1 Extension to the venous system is a feature of cancer progression; however, at diagnosis, venous tumour thrombi are present in only 4-10% of cases. 2 Invasion of the inferior vena cava is not considered a negative prognostic indicator according to the 2002 TNM classification, and this remained the same following the recent 2009 update. 3, 4 Nevertheless, the gravity of this feature is still under debate. 5, 6 The surgical management of renal cancer with tumour thrombi has evolved substantially since it was first documented in 1913, with the first excision of an intracardiac neoplastic thrombus performed under cardiac bypass in 1970. 7 Technical advances have progressively yielded more acceptable morbidity and mortality rates, even though surgical excision of neoplastic thrombi is much more complex than radical nephrectomy. [8] [9] [10] [11] To date, the number of cases reported in the literature by individual centres is limited, and the available multi-centre studies are retrospective.
11,12
Therefore, we wished to review and report the oncological results from our experience with the surgical management of RCC patients with tumour thrombi that had invaded the vena cava.
MATERIALS AND METHODS
Population.
Between 1996 and 2006, 512 cancer patients underwent nephrectomies at our centres. We selected patients who received surgeries for RCC with caval thrombi during this period.
The following data were examined retrospectively: age at diagnosis, sex, smoking status, M A N U S C R I P T Pre-surgical examination.
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The pre-operative evaluation for all patients involved a clinical exam and laboratory tests (creatinine, albumin, haematocrit, electrolytes, coagulation), as well as thoracic, abdominal and pelvic imaging studies.
Surgery.
None of our patients were embolised. The surgical approach was determined by the superior limit of the venous thrombus. For stage I and II diseases, an abdominal approach with a subcostal incision allowed for resection of the thrombus in the retro-and suprahepatic vena cava. For stage III and IV diseases, access to the supradiaphragmatic vena cava was necessary. For stage III disease, this access was achieved either through an abdominal approach, a thoraco-diaphragmatic laparotomy or medial abdominal or subcostal incisions with sternotomy; we chose the approach that was best suited for each patient. For stage IV disease, access to the right atrium required a systematic sternotomy and systematic intervention in the cardiac operating suite.
Complications.
The peri-and immediate post-operative complications were defined according to the Clavien grading system for surgical morbidity. 13 Events defined as Clavien grade I-II or those that required pharmacological intervention and/or nonprocedural deviation from the routine postoperative course were considered minor complications. Major complications (Clavien grade III-IV-V) were defined as events requiring reoperation or unexpected intensive care unit (ICU) management.
Monitoring.
Patients were seen for follow-up appointments 1, 3 and 6 months after surgery, every six months thereafter for two years, and every year thereafter for laboratory tests and thoracic-abdominal-pelvic scans. In cases of local recurrence or metastasis, appropriate treatment was provided.
Statistical analysis.
All patients were followed from diagnosis until death or until data were censored (and the patient was considered to be alive). Patients who had a follow-up period of less than 6 months were not included in the analysis of censored data. Overall survival was evaluated from the date of surgery to the last follow-up visit or death. Recurrence-free survival was defined as the period between the initial surgery and the subsequent appearance of recurrence or metastasis. Kaplan-Meier survival curves were calculated using censured data and compared by the log-rank test. Univariate analyses were used to assess associations between traditional prognostic factors (stage, Fuhrman grade), M A N U S C R I P T A C C E P T E D 
RESULTS
Population.
A total of 32 patients with vena caval tumour thrombi were included in this retrospective study. The male to female ratio was 2. Involvement of the wall of the vena cava was found in ten cases, of which five were diagnosed by pre-operative imaging studies. Total (n = 2) or partial (n = 1) resection of the vena cava was required in three cases; venous grafts, either biologic or prosthetic, were unnecessary.
The mean blood loss was 1900 ± 1600 cc (range 400-7000). Twenty-six patients required intra-operative transfusions with approximately 4.3 ± 3.4 (range 1-17) units of packed red blood cells.
Post-operative period and complications.
The peri-and post-operative data are summarised in Table 2 . The mean duration of hospitalisation was 13.6 ± 7.8 days (range 1-40), of which 3.6 ± 4.5 were in intensive care (range 0-20).
The complication rate was 53%, and seventeen patients experienced one or more postoperative complications. Overall, five patients experienced minor complications, and twelve experienced major complications. Four patients died in intensive care. Three of these patients had received a thoracotomy and died from pulmonary complications; the fourth patient, who had stage I disease, experienced heart failure. No patient required additional surgery in the immediate post-operative period. The following were additional complications: acute renal insufficiency (n = 8) that required temporary dialysis in two cases, sepsis of the pulmonary origin (n = 4), pulmonary embolism (n = 1) and pneumothorax (n = 1). No patient required dialysis after the acute post-operative period.
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Survival and recurrence.
The median follow-up for all stages occurred at 64 months (range 54-100). The five-year overall survival rate for all stages combined was 47% (Figure 1 ). The five-year cancer specific survival rate for all stages was 52%. The median survival of patients was 33 months (range 6-122). Eleven patients underwent adjuvant immuno-or antiangiogenic therapy, either for metastases identified during staging (n = 2) or for local or distant recurrences identified at follow-up (n = 9). Seven patients died from disease progression an average of 56 ± 13 months (range 30-81) after surgery.
Local recurrence and/or metastasis were observed in 18 patients (74%). The mean delay until the first recurrence was 38 ± 10 months (range 19-57; median 17). The five-year recurrence-free survival rate for all stages was 18% (Figure 1 ). Local recurrences were discovered in eight patients after a mean interval of 76 ± 13 months (range 50-101). Four recurrences were in the region of the nephrectomy, and one of these recurrences was accompanied by a recurrence of venous thrombus. There was one recurrence of tumour thrombus alone, and three tumours recurred as retroperitoneal adenopathies, one of which was associated with pulmonary metastases. A single metastatic recurrence was discovered in 11 patients after a mean interval of 55 ± 13 months (range 30-81) from surgery. Local recurrences were treated by surgery alone (n = 2), interferon immunotherapy (n = 2) or anti-angiogenic therapy (n = 2). A unique instance of both local recurrence and metastasis was treated by interferon. Metastases were treated by interferon (n = 1), chemotherapy (n = 2), anti-angiogenic therapy (n = 2) or surgery alone (n = 2). The overall survival rate at five years for all disease stages was 47% (Figure 1) .
The overall five-year survival rate for patients without nodal metastases was 55% compared to 0% for patients with N+ disease.
Univariate analyses revealed that ECOG performance status and Furhman grade expression were both significant factors in survival (p=0.01, p=0.022, respectively) but not venous involvement, regardless of whether that involvement was sub-or supradiaphragmatic (i.e., stage and TNM). However, in a multivariate analysis, no factor was found to be an independent prognostic factor.
DISCUSSION
Survival of RCC patients with venous extension.
The survival of RCC patients who had involvement of the vena cava by tumour thrombi over the last twenty years has already been described. 8, [14] [15] [16] [17] [18] [19] The rate of overall survival in our study, 47% at five years, was similar to rates that have been documented in previous studies (Table 4) . Concomitant involvement of the vena cava at the time of RCC diagnosis was relatively rare; all previous studies are retrospective, are based on long periods (10-30 years) and have small sample sizes. Despite the weak evidence in these studies, they at least permit us to better comprehend these rare cases in terms of morbidity and mortality and give us an idea of the prognostic validity of venous involvement. We also compared this analysis with our study published in 1998, which described 51 patients who received operations at our centre between 1982 and 1995. 20 In that study, we found a five-year patient survival rate of 36% for all stages. The published studies are heterogeneous and in some cases cover periods in excess of 20 years, but the true survival rate for all stages is on the order of 45% after five years ( Table 4 ). The
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10 disease-free survival rate was 18% in our study, which again is consistent with the literature. The traditional prognostic factors are tumour grade and stage. However, the possibility of graduating clinical symptoms for a prognostic purpose has been established 21, 22 and is confirmed by our data because the ECOG performance status was significant. However, other traditional prognostic factors were not found to be significant, likely due to a limited population and lack of power.
TNM staging for RCC with tumour thrombus.
The prognostic significance of venous involvement and tumour thrombus level in RCC remains highly controversial and is still a subject of debate. 5, 6 According to the 2002 TNM classification, the involvement of the inferior vena cava by tumour thrombi is equivalent to involvement of the renal vein. 4 We have described the difference in survival Further perspectives for the treatment of RCC with venous extension.
The role of anti-angiogenesis in the management of RCC with venous tumour thrombi is also not well defined. It is important to underline the "dilemma" and the ongoing debate about the role of systemic treatment with new drugs either in the preoperative or in the post-operative setting. In our study, we administered anti-angiogenic agents as a neoadjuvant therapy. The neoadjuvant use of these agents has two distinct objectives:
either to enable resection of a lesion that is initially inoperable or to lower the tumour (9) III (6) IV (9) 
